胆汁淤积性肝病的正确认识与科学管理

doi:10.3969/j.issn.1672-5069.2019.05.036

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (5): 754-757.doi: 10.3969/j.issn.1672-5069.2019.05.036

胆汁淤积性肝病的正确认识与科学管理

陆伦根

200080 上海市交通大学附属第一人民医院消化科

收稿日期:2019-07-20 出版日期:2019-09-10 发布日期:2019-09-16
通讯作者: 陆伦根,男,54岁,教授,博士生导师。E-mail: lungenlu1965@163.com

Cholestatic liver diseases：What we know and how to deal with

Lu Lungen

Department of Gastroenterology,First People’s Hospital,Affiliated to Jiaotong University,Shanghai 200080

Received:2019-07-20 Online:2019-09-10 Published:2019-09-16

摘要/Abstract

关键词: 胆汁淤积性肝病, 管理

Key words: Cholestatic liver diseases, Primary biliary cholangitis, Primary sclerosing cholangitis, Ursodeoxycholic acid, Therapy

陆伦根. 胆汁淤积性肝病的正确认识与科学管理[J]. 实用肝脏病杂志, 2019, 22(5): 754-757.

Lu Lungen. Cholestatic liver diseases：What we know and how to deal with[J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.

[1] Kuntz K,Kuntz HD.Cholestasi. Hepatology:principles and practice. 2nd ed. Springer Medizin Verlag Heidelberg,2006:227-242.
[2] 中华医学会肝病学分会、消化病学分会、感染病学分会.胆汁淤积性肝病诊断和治疗共识(2015). 实用肝脏病杂志,2016,19(6):Ⅰ-ⅩⅠ.
[3] European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of cholestatic liver diseases. J Hepatol,2009,51:237-267.
[4] Beuers U,Kremer AE,Bolier R,et al.Pruritus in cholestasis: facts and fiction. Hepatology,2014,60:399-407.
[5] Lu LG .Current situation in basic and clinical research on cholestatic liver diseases. 中华肝脏病杂志,2008,16:561-563.
[6] Jungst C,Lammert F.Cholestatic liver disease. Dig Dis,2013,31:152-154.
[7] Paumgartner G,Beuers U.Ursodeoxycholic acid in cholestatic liver disease:mechanisms of action and therapeutic use revisited. Hepatology,2002,36:525-531.
[8] Lindor KD,Kowdley KV,Luketic V a C,et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology,2009,50(3): 808-814.
[9] Lu SC,Mato JM.S-adenosylmethionine in liver health,injury,and cancer. Physiol Rev,2012,92(4):1515-1542.
[10] Carrion AF,Rosen JD,Levy C.Understanding and treating pruritus in primary biliary cholangitis. Clin Liver Dis,2018,22(3):517-532.
[11] Panebianco C,Oben J A,Vinciguerra M,et al.Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal:a putative synergy between retinoic acid and PPAR-gamma signalings. Clin Exp Med,2017,17(3):269-280.
[12] Assis D N,Abdelghany O,Cai SY,et al.Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis:A human pilot study. J Clin Gastroenterol,2017,51(2):e11-e16.
[13] Wahlström A,Kovatcheva-Datchary P,Stöhlman M,et al. Crosstalk between bile acids and gut microbiota and tts impact on Farnesoid X receptor signalling. Dig Dis,2017,35(3):246-250.
[14] Kowdley K V,Luketic V,Chapman R,et al.A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology,2018,67(5):1890-1902.
[15] De Vries E,Beuers U.Management of cholestatic disease in 2017. Liver Int,2017,37(S1):123-129.
[16] Reig A,Sesé P,Parés A.Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol,2018,113(1): 49-55.
[17] Santiago P,Scheinberg A R,Levy C.Cholestatic liver diseases:new targets,new therapies. Therap Adv Gastroenterol,2018,11:1756284818787400-1756284818787400.
[18] Tabibian J H,Weeding E,Jorgensen R A,et al.Randomised clinical trial:vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study. Aliment Pharmacol Ther,2013,37(6):604-612.
[19] Fickert P,Hirschfield G M,Denk G,et al.Nor ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol,2017,67(3):549-558.
[20] Li W,Qin H,Hua C,et al.Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis. Stem Cells Dev,2014,23(20):2482-2489.

胆汁淤积性肝病的正确认识与科学管理

Cholestatic liver diseases：What we know and how to deal with

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	丁雯瑾, 范建高. 胆汁淤积性肝病相关并发症的处理^*[J]. 实用肝脏病杂志, 2019, 22(6): 938-940.
[2]	中华医学会肝病学分会, 中华医学会消化病学分会. 终末期肝病临床营养指南[J]. 实用肝脏病杂志, 2019, 22(5): 624-635.
[3]	洪佳, 吴晓宁, 尤红. 胆汁淤积性肝病的规范化诊断[J]. 实用肝脏病杂志, 2019, 22(5): 758-760.
[4]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[5]	丁洋, 窦晓光. 如何实现乙型肝炎病毒母婴“零”传播?[J]. 实用肝脏病杂志, 2019, 22(1): 4-5.
[6]	朱娅鸽, 雷春梅, 郭丹丹, 陈天艳. 慢性乙型肝炎病毒感染孕妇及其婴幼儿随访管理研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 45-48.
[7]	杨蕊旭, 范建高. 欧洲失代偿期肝硬化并发症管理指南简介[J]. 实用肝脏病杂志, 2018, 21(4): 496-501.
[8]	于爱东, 王传杰, 李建芳. 群组管理模式对提高慢性乙型肝炎患者抗病毒治疗依从性的作用研究[J]. 实用肝脏病杂志, 2018, 21(4): 621-622.
[9]	郭伟, 赵金玉, 齐春燕. 疼痛管理对癌晚原发性肝期患者生命质量的影响分析^*[J]. 实用肝脏病杂志, 2018, 21(4): 641-642.
[10]	陈杰, 范作鹏, 梁珊, 聂巍, 仇丽霞, 杨海霞, 林伟, 刘义荣, 张晶, 胡中杰. 合并慢性胆汁淤积性肝病对慢性药物性肝损害患者临床表现及对治疗应答的影响*[J]. 实用肝脏病杂志, 2017, 20(6): 720-723.
[11]	施漪雯，尤红. 重视胆汁淤积性肝病的诊断和药物治疗[J]. 实用肝脏病杂志, 2016, 19(6): 641-643.
[12]	沈斐斐，陆伦根. 胆汁淤积性肝病的病因[J]. 实用肝脏病杂志, 2016, 19(6): 644-646.
[13]	朱疆依，韩英. 关于胆汁淤积性肝病诊断的几点探讨[J]. 实用肝脏病杂志, 2016, 19(6): 647-649.
[14]	阎俪，马雄. 胆汁淤积性肝病的治疗[J]. 实用肝脏病杂志, 2016, 19(6): 650-653.
[15]	参加慢性乙型肝炎长期治疗讨论会专家. 核苷和核苷酸类药物治疗慢性乙型肝炎的长期性[J]. 实用肝脏病杂志, 2015, 18(1): 113-119.